Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells

American Journal of Cancer Research

Volumn 5, Issue 5, 2015, Pages 1649-1664

  Demel, Hans Richard ^a   Feuerecker, Benedikt ^a   Piontek, Guido ^a   Seidl, Christof ^a   Blechert, Birgit ^a   Pickhard, Anja ^a   Essler, Markus ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Apoptosis; Cancer treatment; Cell survival; DNA damage response; Glucose metabolism; PI3K Akt mTor pathway; Topoisomerase inhibitors

Indexed keywords

EID: 85006200875     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ciccia A and Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
2. Finlay MR and Griffin RJ. Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett 2012; 22: 5352-5359.
3. Lord CJ and Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
4. Furgason JM and Bahassi el M. Targeting DNA repair mechanisms in cancer. Pharmacol Ther 2013; 137: 298-308.
5. Woods D and Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther 2013; 14: 379-389.
6. Bakkenist CJ and Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
7. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-350.
8. Caldecott K, Banks G and Jeggo P. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 1990; 50: 5778-5783.
9. Shen H, Schultz M, Kruh GD and Tew KD. Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. Biochim Biophys Acta 1998; 1381: 131-138.
10. Hansen LT, Lundin C, Helleday T, Poulsen HS, Sorensen CS, Petersen LN and Spang-Thomsen M. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 2003; 40: 157-164.
11. Lans H, Marteijn JA and Vermeulen W. ATP-dependent chromatin remodeling in the DNA-damage response. Epigenetics Chromatin 2012; 5: 4.
12. Kinoshita E, van der Linden E, Sanchez H and Wyman C. RAD50, an SMC family member with multiple roles in DNA break repair: how does ATP affect function? Chromosome Res 2009; 17: 277-288.
13. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
14. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
15. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB and Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004; 16: 819-830.
16. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL and Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005; 24: 4165-4173.
17. Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
18. Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 2009; 315: 485-497.
19. Nakano A, Miki H, Nakamura S, Harada T, Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T and Abe M. Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. J Bioenerg Biomembr 2012; 44: 31-38.
20. Xu N, Lao Y, Zhang Y and Gillespie DA. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012; 2012: 951724.
21. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T and Imura H. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-230.
22. Binder C, Binder L, Marx D, Schauer A and Hiddemann W. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res 1997; 17: 4299-4304.
23. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 1999; 56: 285-292.
24. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y and Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33: 683-691.
25. Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, Yasui T, Sumi T, Honda K and Ishiko O. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 2007; 18: 361-367.
26. Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A and Watanabe Y. Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol 2007; 43: 563-569.
27. Pedersen PL, Mathupala S, Rempel A, Geschwind JF and Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002; 1555: 14-20.
28. Pelicano H, Martin DS, Xu RH and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
29. Mathupala SP, Ko YH and Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19: 17-24.
30. Czernin J and Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53: 89-112.
31. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009; 50 Suppl 1: 1S-10S.
32. Zhou R, Vander Heiden MG and Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 2002; 62: 3515-3520.
33. Watanabe M, Naraba H, Sakyo T and Kitagawa T. DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. Mol Cancer Res 2010; 8: 1547-1557.
34. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
35. Brown RS and Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72: 2979-2985.
36. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F and Beger HG. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-1348.
37. Macheda ML, Rogers S and Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-662.
38. Adams V, Kempf W, Hassam S and Briner J. Determination of hexokinase isoenzyme I and II composition by RT-PCR: increased hexokinase isoenzyme II in human renal cell carcinoma. Biochem Mol Med 1995; 54: 53-58.
39. Vaughn AE and Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 2008; 10: 1477-1483.
40. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B and Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-1559.
41. Kaina B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol 2003; 66: 1547-1554.
42. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH and Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001; 21: 5899-5912.
43. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, Sakai A, Ozaki S, Okano K, Nakamura T, Itoh K, Matsumoto T and Abe M. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 2011; 6: e27222.
44. Fletcher JI, Haber M, Henderson MJ and Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-156.
45. Kelly CJ, Hussien K and Muschel RJ. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition. Nucl Med Biol 2012; 39: 986-992.
46. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N and Burma S. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia 2012; 14: 34-43.
47. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC and Mitsiades CS. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-5842.
48. Muller A, Zang C, Chumduri C, Dorken B, Daniel PT and Scholz CW. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer 2013; 133: 1813-1824.
49. Stengel C, Cheung CW, Quinn J, Yong K and Khwaja A. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012; 26: 1761-1770.
50. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406-1418.
51. Korwek Z, Sewastianik T, Bielak-Zmijewska A, Mosieniak G, Alster O, Moreno-Villanueva M, Burkle A and Sikora E. Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells. DNA Repair (Amst) 2012; 11: 864-873.
52. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23: 1895-1909.
53. Bozulic L, Surucu B, Hynx D and Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30: 203-213.